Literature DB >> 20886344

Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway.

Yun Tian1, Ying Ye, Wei Gao, Hong Chen, Ting Song, Daqing Wang, Xiaoyun Mao, Changshan Ren.   

Abstract

BACKGROUND AND AIMS: Aspirin is associated with a reduced risk of colorectal cancer (CRC), and it showed inhibited effects on interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway which is thought to play an important role in intestinal inflammation and the tumorigenesis of CRC.
METHODS: Mouse model for inflammation-related CRC was induced by a combined treatment with azoxymethane (AOM) and dextran sodium sulfate (DSS) in BALB/c mice. Effects of aspirin on tumor number and size and apoptosis of CRC cells were investigated. Key molecules of IL-6-STAT3 pathway, such as IL-6, sIL-6R, phosphorylated STAT3, and their downstream anti-apoptotic genes Bcl-2 and Bcl-xl, were assessed by ELISA and Western blot.
RESULTS: Treatment with aspirin significantly promoted CRC cell apoptosis in AOM/DSS-induced CRC mice in vivo. The expression level of IL-6, which is an upstream molecule of STAT3 and capable of activating STAT3, was reduced in aspirin-treated mice. Furthermore, the phosphorylated form of STAT3 and the levels of STAT3's target gene products such as Bcl-xl and Bcl-2, which are essential for cell growth and survival, were also decreased in aspirin-treated mice.
CONCLUSIONS: Our data suggested that the protective mechanisms of aspirin in CRC may be associated with its effects on induction of CRC cell apoptosis and suppression of IL-6-STAT3 signaling pathway, which implied that aspirin has a potential therapeutic activity in CRC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886344     DOI: 10.1007/s00384-010-1060-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  41 in total

1.  Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut.

Authors:  E Kankuri; K Vaali; R Korpela; I Paakkari; H Vapaatalo; E Moilanen
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

2.  Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice.

Authors:  Rikako Suzuki; Hiroyuki Kohno; Shigeyuki Sugie; Hitoshi Nakagama; Takuji Tanaka
Journal:  Carcinogenesis       Date:  2005-08-04       Impact factor: 4.944

3.  Promotion of colorectal neoplasia in experimental murine ulcerative colitis.

Authors:  I Okayasu; T Ohkusa; K Kajiura; J Kanno; S Sakamoto
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

4.  Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine.

Authors:  Masayuki Fukata; Anli Chen; Arielle Klepper; Suneeta Krishnareddy; Arunan S Vamadevan; Lisa S Thomas; Ruliang Xu; Hiroyasu Inoue; Moshe Arditi; Andrew J Dannenberg; Maria T Abreu
Journal:  Gastroenterology       Date:  2006-09       Impact factor: 22.682

5.  Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis.

Authors:  Hong-Gang Yu; Liang-Liang Yu; Yanning Yang; He-Sheng Luo; Jie-Ping Yu; Juris J Meier; Henning Schrader; Andreas Bastian; Wolfgang E Schmidt; Frank Schmitz
Journal:  Oncology       Date:  2003       Impact factor: 2.935

6.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

7.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

Authors:  Bernard F Cole; Richard F Logan; Susan Halabi; Robert Benamouzig; Robert S Sandler; Matthew J Grainge; Stanislas Chaussade; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

8.  Association of early phase of colorectal carcinogenesis with STAT3 activation and its relevance in apoptosis regulation.

Authors:  Rathindranath Baral; Anamika Bose; Chinmoyee Ray; Sonali Paul; Smarajit Pal; Enamul Haque; Bhagawan Mishra; Debolina Pal; Jatin Kumar Nagpal; Chinmay Kumar Panda; Bibhu Ranjan Das
Journal:  Exp Mol Pathol       Date:  2009-03-31       Impact factor: 3.362

9.  Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study.

Authors:  Søren Friis; Aslak H Poulsen; Henrik Toft Sørensen; Anne Tjønneland; Kim Overvad; Ulla Vogel; Joseph K McLaughlin; William J Blot; Jørgen H Olsen
Journal:  Cancer Causes Control       Date:  2009-01-03       Impact factor: 2.506

Review 10.  Inflammation and colorectal cancer.

Authors:  Sarah Kraus; Nadir Arber
Journal:  Curr Opin Pharmacol       Date:  2009-07-07       Impact factor: 5.547

View more
  20 in total

1.  Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq.

Authors:  Yue Guo; Zheng-Yuan Su; Chengyue Zhang; John M Gaspar; Rui Wang; Ronald P Hart; Michael P Verzi; Ah-Ng Tony Kong
Journal:  Biochem Pharmacol       Date:  2017-03-04       Impact factor: 5.858

2.  TGF-β1 mediates the effects of aspirin on colonic tumor cell proliferation and apoptosis.

Authors:  Yuyi Wang; Chi Du; Nan Zhang; Mei Li; Yanyang Liu; Maoyuan Zhao; Feng Wang; Feng Luo
Journal:  Oncol Lett       Date:  2018-02-14       Impact factor: 2.967

3.  The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice.

Authors:  Yue Guo; Yue Liu; Chengyue Zhang; Zheng-Yuan Su; Wenji Li; Mou-Tuan Huang; Ah-Ng Kong
Journal:  Carcinogenesis       Date:  2016-04-09       Impact factor: 4.944

4.  Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs in vivo and in vitro.

Authors:  Lenard M Lichtenberger; Tri Phan; Dexing Fang; Elizabeth J Dial
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

5.  Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2.

Authors:  Wen Yue; Xi Zheng; Yong Lin; Chung S Yang; Qing Xu; Darren Carpizo; Huarong Huang; Robert S DiPaola; Xiang-Lin Tan
Journal:  Oncotarget       Date:  2015-08-28

6.  Aspirin Protects against Acinar Cells Necrosis in Severe Acute Pancreatitis in Mice.

Authors:  Guotao Lu; Zhihui Tong; Yanbing Ding; Jinjiao Liu; Yiyuan Pan; Lin Gao; Jianfeng Tu; Yuhui Wang; George Liu; Weiqin Li
Journal:  Biomed Res Int       Date:  2016-12-29       Impact factor: 3.411

7.  Sodium salicylate modulates inflammatory responses through AMP-activated protein kinase activation in LPS-stimulated THP-1 cells.

Authors:  Weiwei Bao; Yaru Luo; Dan Wang; Jian Li; Xi Wu; Wei Mei
Journal:  J Cell Biochem       Date:  2017-08-30       Impact factor: 4.429

8.  Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate.

Authors:  Elisa Brighenti; Ferdinando Antonino Giannone; Francesca Fornari; Carmine Onofrillo; Marzia Govoni; Lorenzo Montanaro; Davide Treré; Massimo Derenzini
Journal:  Oncotarget       Date:  2016-09-27

9.  Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer.

Authors:  Qinghong Hu; Abha Hada; Liping Han
Journal:  J Ovarian Res       Date:  2020-07-18       Impact factor: 4.234

10.  Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators.

Authors:  Thomas Köhnke; Beate Gomolka; Süleyman Bilal; Xiangzhi Zhou; Yanping Sun; Michael Rothe; Daniel C Baumgart; Karsten H Weylandt
Journal:  Biomed Res Int       Date:  2013-09-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.